News | December 07, 2010

Bioresorbable Stent Overinflates Without Cracking or Crazing


December 7, 2010 – A new bioresorbable stent scaffold can be overinflated by more than 25 percent without cracking or crazing. New data from Arterial Remodeling Technologies (ART) show that its bioresorbable polylactic acid (PLA) stent platform is designed to avoid malapposition.

With conventional stents a gap between the vessel and the stent can manifest. This "malapposition" of stent struts within the vessel has been shown to occur in conventional stent placements and is a significant risk factor in stent thrombosis. Additionally, data on other bioresorbable stents showed that when the struts have been overinflated to compensate for potential malapposition, they have cracked or crazed. This may lead to a life-threatening coronary event.

The company’s stent is designed to have a faster and smoother resorption; a non-crystalline polymer; better, homogeneous stress diffusion; and crack- and crazing-free expansion. In addition, the device is designed to be delivered by conventional stenting techniques, is balloon-expandable and meets the market standard of 6-French compatibility.

For more information: www.art-stent.com


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now